The authors reported a reduced sodium current, increased triggered action potential activity, and abnormal Ca2+ transients in the Brugada syndrome patient-derived cells in one of the patient-derived iPS cell lines the SCN5A mutation (c.4190delA) was edited using the CRISPR/Cas9-mediated genome editing technology. This evidence concerns the gene SCN5A and Brugada syndrome.